|
DBM: General Mandate 2018
On 26 Apr 2018, DakLak Pharmaceutical Medical Equipment Joint Stock Company announced the General Mandate 2018 as follows:
Article 1: Approve report of Board of Directors on operation results of 2017 and operation plan 2018
1. Operation results of 2017
- Revenue: 271,494 million dongs, equivalent to 90.5% of the plan
- Profit after tax: 6,831 million dongs, equivalent to 105.1% of the plan
- Earnings per share: VND 3,519
- Dividend payment: 12%, equivalent to 100% of the plan
2. Operation plan 2018
- Revenue: 300,000 billion dongs
- Profit after tax: 6,500 million dongs
Article 2: Approve operation results of 2017 and operation plan 2018
Article 3: Approve statement on audited financial statement 2017
Some major indicators
1. Total assets: VND 102,982,820,606
2 Owner's equity: VND 54,946,251,088
3. Net Revenue from sale of goods and services: VND 271,494,964,802
4. Cost of goods sold: VND 240,102,917,156
5. Sales expense: VND 17,281,135,642
6. General and administrative expense: VND 8,607,617,498
7. Profit after tax: VND 6,831,708,433
Article 4: Approve report 2017 of Supervisory Board on statement on selecting an auditor to audit financial statement 2018
Article 5: Approve statement on profit distribution 2017 and profit distribution plan 2018
1. Dividend payment
a. Dividend payment 2017 (12%/ charter capital): VND 2,329,905,600
b. Remuneration for Board of Directors and Supervisory Board: VND 400,000,000
c. Appropriation for funds:
- Reward fund to Management Board: VND 340,000,000
- Welfare Reward Fund: VND 800,000,000
- Investment Development Fund: VND 3,361,802,833
2. Profit distribution 2018
a. Dividend payment: 12%/ charter capital
b. Remuneration for Board of Directors and Supervisory Board: VND 400,000,000
c. Appropriation for funds:
- Reward fund to Management Board: 5% of profit after tax (in case of completing indicators of annual General Meeting of Shareholders 2018)
Article 6: Approve Statement on signature and implementation of contracts with Traphaco Joint Stock Company
Article 7: Approve Statement on amended and supplemented Charter of DakLak Pharmaceutical Medical Equipment Joint Stock Company
Article 8: Approve Statement on issuing internal corporate governance regulation
Article 9: The annual General Meeting of Shareholders approved assigning Board of Directors and Supervisory Board to carry out the General Mandate in accordance with regulations
The General Mandate 2018 was approved by annual General Meeting of Shareholders 2018 and took effect from 26 Apr 2018
HNX
|
